Tue Sep 17 07:24:53 UTC 2024: ## Principal Financial Group Cuts Relay Therapeutics Stake, Other Investors Show Interest

**New York, NY – September 17, 2024** – Principal Financial Group Inc. has decreased its stake in Relay Therapeutics, Inc. (NASDAQ:RLAY) by 43.4% during the second quarter, according to a recent filing with the Securities and Exchange Commission. The institutional investor now owns 14,580 shares of the company’s stock, valued at $95,000.

Despite Principal Financial Group’s reduction, other institutional investors have shown interest in Relay Therapeutics. Victory Capital Management Inc. purchased a new stake in the fourth quarter worth about $126,000. Meanwhile, Charles Schwab Investment Management Inc. increased its position by 22.8% during the same period, now owning 877,813 shares worth $9,665,000. Norges Bank also acquired a new position in the fourth quarter, valued at approximately $33,789,000.

Relay Therapeutics operates as a clinical-stage precision medicines company, focusing on enhancing small molecule therapeutic discovery in oncology and genetic diseases. The company’s lead product candidates are currently undergoing clinical trials for various cancer types.

Shares of RLAY opened at $8.11 on Tuesday. The company has a market cap of $1.09 billion and a PE ratio of -3.07. Several brokerages have recently commented on RLAY, with some analysts maintaining a “buy” rating while others have lowered their price objectives.

“The recent activity from institutional investors suggests a continued interest in Relay Therapeutics despite some adjustments in holdings,” commented a market analyst. “The company’s focus on precision medicine and its pipeline of promising product candidates continue to attract attention.”

Overall, the stock’s performance remains a subject of debate among analysts, with a mixed outlook for the future.

Read More